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Abstract  
 
Introduction: Quality indicators are increasingly used as a tool to achieve safe and quality 
clinical care, cost-effective therapy, for professional learning, remuneration, accreditation and 
financial incentives. A substantial number focus on drug therapy but few address the 
introduction of new medicines even though this is a burning issue. Objective: Describe the 
issues and challenges in designing and implementing a transparent indicator framework and 
evaluation protocol for the introduction of new medicines and to provide guidance on how to 
apply quality indicators in the managed entry of new medicines. Results: Quality indicators 
need to be developed early to assess whether new medicines are introduced appropriately. A 
number of key factors need to be addressed when developing, applying and evaluating 
indicators including dimensions of quality, suggested testing protocols, potential data sources, 
key implementation factors such as intended and unintended consequences, budget impact 
and cost-effectiveness, assuring the involvement of medical professions, patients and the 
public, and reliable and easy-to-use computerised tools for data collection and management. 
Transparent approaches include the need for any quality indicators developed to handle 
conflicts of interests to enhance their validity and acceptance.  Conclusion: The suggested 
framework and indicator testing protocol may be useful in assessing the applicability of 
indicators for new medicines and may be adapted to health care settings worldwide. The 
suggestions build on existing literature to create a field testing methodology that can be used 
to produce country specific quality indicators for new medicines as well as a pan-international 
approach to facilitate access to new medicines.  
 
Introduction 
 
Drug therapy and vaccines play an important role in prevention and treatment of many 
diseases. During the last decades, new drugs and vaccines have markedly decreased mortality 
and hospital care and have improved the quality of life for millions of people in lower income 
as well as in higher income countries 1. However, if these drugs and vaccines are used 
improperly, the negative or unintended consequences can outweigh their benefits. In some 
cases, inappropriate use may result simply in the absence of any clinical effect or result in a 
similar clinical effect but at a greater cost; however, there is also potential for increased 
morbidity and mortality 2-5. The consequences can be costly such as adverse drug reactions 
(ADRs) in particular in older people and in those with multiple chronic conditions, adding to 
the costs of healthcare by increasing hospital admissions. 4-6 There is however a recognised 
efficacy-effectiveness gap due to the variation/uncertainty about efficacy and safety when 
new medicines are introduced. 7 
 
The introduction of new medicines challenges the ability of European countries to meet 
Article 3 of the European Convention on Human Rights and Biomedicine 8 , in terms of being 
able to provide equitable and comprehensive healthcare. 8-12  This is because pharmaceutical 
expenditure has been growing by 50% in real terms during the past decade13 and this increase 
is already leading to new premium priced drugs not being funded in some countries. 9,14 
Consequently, the appropriate and safe use of new medicines needs to be introduced with a 
clear plan both before and after market authorisation to optimise their real world use. This can 
be undertaken using proposed models centred on the three pillars of pre-, peri- and post-
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launch activities aiming for transparency about medical needs, drug use and involving all key 
stakeholder groups. 9,11,12    
 
Quality indicators are used increasingly for benchmarking, as an auditing tool, or to measure 
the effect of interventions. 15-20Many indicators integrate drug therapy with other aspects of 
quality of care or link to a procedure such as changes to treatment. 21,22 Initiatives have also 
been taken to develop specific indictors focusing on the rational use of medicines 15 
particularly for the treatment of common diseases 15, 22,23 as well as patient safety. 24 
Corresponding initiatives for medicines introduced in specialist care have been lacking 
despite the rapid changes in the drug market, with more and more new biologic drugs being 
introduced for the treatment of cancer and autoimmune diseases. 5,25-27 
  
There are various types of indicators with different requirements and purposes.28-39 They are  
important embed in the definition of rational use of medicines as a goal in quality of 
medicines use, which is ³patients receive medication appropriate to their medical needs, in 
doses meeting their own individual requirements, for an adequate period of time and at the 
lowest cost to them and to the community´. 11,12  Consequently, effective management of costs 
is also included in high quality of medicines use. 
 
Indicators designed to assess quality should adhere to a clear definition of quality of care and 
include key measurement attributes 30-34 with an a priori clear definition and purpose for use.  
They must be integrated within implementation and quality improvement programmes35and 
specific to the appropriate level of the health care system i.e. micro, meso or macro 36-37 and 
be related to structure, process or outcome 15,30,31  
 
Indicators may be valuable tools in the managed introduction of new medicines.  A distinction 
is needed between using quality indicators as part of a testing protocol or as part of an overall 
management plan, which is implemented to accompany the indroduction of new medicines. 
The aim of this paper is to describe the issues and challenges in designing and implementing 
an indicator framework and evaluation protocol for the introduction of new medicines in 
ambulatory and specialist/hospital care settings, which we believe will be potentially useful in 
European healthcare systems. 
 
Key issues when introducing new medicines 
 
When introducing new premium priced medicines that improve the health of patients,  models 
are essential to optimise their cost-effective prescribing. Concerns include the potential 
budget impact, safety and/or effectiveness when the new medicine is used in populations 
other than those studied in randomised clinical trials 4,7,9-11,38-42. This is because whilst only a 
limited number of new medicines are truly innovative, there is a need to fund these at 
premium prices in patient populations where they provide greatest value to address the 
considerable areas of unmet need that still exist in Europe and globally42-45. Otherwise 
typically reimbursed at lower prices than current standards 12,38. Deliberations on these 
concerns led to a proposed model to optimise the managed entry of new drugs pre-, peri- and 
post launch 9,11,38,42. Proposed activities range from early warning systems pre-launch to 
monitoring physician prescribing post-launch. 
 
Key issues affecting the value of new medicines pre- to peri-launch  include the weak 
evidence based on the published literature, a mismatch between efficacy and effectiveness 
(expectations from clinical trials), limited data available in the public domain, conflicting 
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views between stakeholders (e.g. on how rapidly drugs should be introduced), the lack of 
guidelines or other recommendations for comparison, difficulties in setting target levels for 
treatment and commonly the small number of patients involved in trials.7,9-11 A systems level 
approach is required within a framework that addresses issues relating to the structure-
process-outcome building on the suggested model for introducing new medicines. 9,11,36,37 A 
number of measures have been introduced to influence drug utilization post-launch. These 
include prescribing guidelines, cross-disciplinary quality work by physicians including 
continuous education organized by Drug and Therapeutics Committees , monitoring of 
prescribing, physician financial incentive schemes and prescribing restrictions 9,18,38,39,41. 
Prescribing restrictions can include prior authorisation by the health authority else 100% co-
payment38. Such demand-VLGHPHDVXUHVKDYHEHHQFROODWHGXQGHUWKH³(V´LHHGXFDWLRQ
engineering, economics and enforcement 16,38,39. While these measures and approaches are 
well developed, the assessment of their impact needs further investigation when applying 
these to the introduction of new medicines. 
 
Indicators must address the timeline of pre-launch, launch and post launch activities for new 
medicines. For example, structure indicators defining and forecasting the capacity of the 
health system to handle the new drug should be developed before the new drug is available on 
the market especially where there are uncertainties regarding its clinical value, and to provide 
pertinent information to patients 5,9,41,42. Without such initiatives, new medicines may struggle 
for funding41,42. 
 
Suggested indicators for new medicines 
 
Suggested indicators for the rational introduction of new medicines can be classified using the 
framework for assessing quality: structure, process and outcome (Table 1) 15,30 and be 
grouped, depending on the included clinical information, into drug-specific, disease-specific 
and patient specific indicators.  
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Table 1. Dimensions of quality in applicable for drug utilization studies. Developed from 
Campbell et al 2000 31  
 
STRUCTURES 
Domain Dimension Examples or areas where quality indicators 
could be developed 
Physical 
characteristics 
Resources Financial, personnel, buildings, equipment, 
availability of information, clinical data and 
registries 
 Organisation of resources Provider continuity, organization of prescribing 
and supply of medicines 
 Management Administration; operational and strategic 
management to support rational drug prescribing, 
e.g. Drug and Therapeutics Committees 
Workforce 
characteristics 
Skill-mix Skills/knowledge of staff 
 Teamworking Team functioning; Delegation, role in promoting 
quality of medicines use 
Systems 
characteristics 
Engineering activities Organizational or managerial interventions such 
as prescribing targets, price: volume  agreements 
 Educational activities Extent and nature of prescribing guidance. These 
may range from simple distribution of printed 
material to more intensive strategies such as 
educational outreach visits by trained facilitators. 
 Economic interventions Patient co-payment including tier levels, positive 
and negative financial incentives and budgets for 
physicians and pharmacists 
 Enforcement Regulations by law and prescribing restrictions 
for physicians for new medicines 
PROCESSES 
Domain Dimension Examples or areas where quality indicators 
could be developed 
Clinical care 
-acute 
-chronic 
-preventive 
 History taking incl. medication history; relevant 
measures taken (e.g. lab test) when initiating 
drug treatment, appropriate drug prescribing, 
medicines reconciliation  
 
Inter-personal 
aspects of care 
 Information exchange/ Communication with 
patients, patient adherence and persistence 
OUTCOME   
Domain Dimension Examples or areas where quality indicators 
could be developed 
Health status Freedom from disease, 
comfort, longevity 
Functional status, symptom relief, quality of Life 
Year. May include both positive effects of the 
drug therapy and negative consequences such as 
hospitalizations and adverse events.  
User evaluation HRQOL Satisfaction 
Communication, Self-esteem 
Systems Efficiency, efficacy and 
equity 
May include patient outcome at a population 
level but also outcome of interventions to 
promote rational use of drugs 
* $FWLYLWLHVWRSURPRWHTXDOLW\RISUHVFULELQJ7KHVHKDYHEHHQFDWHJRUL]HGXVLQJWKHIRXU(V¶(GXFDWLRQ
Engineering, Economics and Enforcement (Wettermark et al 2009) 16. 
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a) Structure indicators 
Indicators describe the structure, capacities and resources needed in a health system for 
monitoring the managed introduction and follow up of new medicines. Examples of such 
indicators include: 
x Structured process for horizon scanning in place pre-launch. Horizon scanning refers to 
early warning systems for forecasting drug utilization and expenditure 25 and seeks to 
examine the potential impact on patient care of new medicines that are expected to receive 
marketing authorisation and their potential threats, opportunities and likely future 
developments. It is important for initiating research or to forecast best practice 
x Access to competence in Health Technology Assessment/evidence based medicine - to 
assess the value of new therapies pre- to peri-launch 
x Proportion of target physicians who have received education around the new therapy pre- 
to peri-launch 
x Proportion of clinics that have implemented a structured protocol to monitor the 
prescribing of the new medicine 
x Proportion of all new drugs launched during the year for which the Drugs and 
Therapeutics Committee (or other relevant stakeholder) has issued guidelines/ 
recommendations for their use  
x Incentives for quality assessment in routine clinical care of new medicines 
x Price: volume agreements or other managed entry arrangements in place to reduce the 
uncertainty around the budget impact of new premium priced medicines46,47.  
x Structure to facilitate interaction and dialogue between relevant health professionals i.e. 
physicians and pharmacists 
 
b) Process indicators ± drug specific with aggregated data 
Diffusion patterns of new medicines may be assessed using readily available aggregate sales 
data. The uptake of new medicines should be compared with existing alternatives, stratified 
by age, gender, diagnosis and geography 48. Without patient identity data, the number of 
DDDs/1000 inhabitants/day (DDD/ TID DDDs = defined daily doses defined as µthe average 
maintenance dose of a drug when used in its major indication in adults¶49) or DDDs/100 bed-days 
can be used as an estimate of the proportion of the population exposed to the new 
medicines49. However, they are only applicable if there is only one indication (and one DDD) 
for the new medicine. 
 
Examples of such indicators include: 
x The proportion of a new drug in a pharmacological group (% DDD or expenditure), e.g.: 
proportion of DPP-IV inhibitors (A) as a % of all oral antidiabetic drugs (B) (A/B *100). 
(Dipeptidyl peptidase-4 inhibitors [DPP-4 inhibitor] ± is a vegetarian enzyme formulation 
with dipeptidyl peptidase IV)50 
x The overall volume of new medicines in a geographical area, e.g., volume of fingolimod 
(DDD/ TID) where the treatment of multiple sclerosis is the only approved indication 
 
These may also include monitoring of drug therapies with patient identity data, i.e.: 
x Proportion of patients initiated on the anti-arrythmic drug dronedarone for whom liver 
function is controlled ± (Dronedarone  is a antiarrhythmic agent pharmacologically related 
to amiodarone but developed to reduce the risk of side effects51) 
x Proportion of patients with HIV tested for CCR5-tropic HIV prior to being prescribed 
maraviroc 5 
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x Proportion of patients initiated on an angiotensin receptor blocker (ARB) having 
previously been treated with an angiotensin enzyme converting inhibitor (ACEI) 52 
x Proportion of elderly patients initiated on the oral anticoagulant drug dabigatran for whom 
their renal function is assessed before starting therapy 9,41,42 
x Proportion of patients initiated on a new oral anti-coagulant (NOAC) for whom their INR 
was not adequately controlled with warfarin9,42,53 
 
c) Process indicators ± drug specific with patient identity data 
The opportunities to develop indicators improve dramatically with the increasing availability 
of encrypted patient identifiers that facilitate studies of the incidence and the prevalence of 
drug use 48,54,55. The incidence and prevalence may then be assessed in relation to other 
treatment alternatives and/or the incidence or prevalence of the target disease.  
 
Other drug-specific indicators that could be derived from patient identity data include the 
proportion of patients initiated on a new medicine previously treated with the first line drug, 
e.g.: 
x Proportion (%) of patients prescribed DPP-IV inhibitors previously treated with 
metformin (A/B * 100 where A = all patients prescribed a DPP-IV inhibitor previously 
treated with metformin and B = all patients prescribed a DPP-IV inhibitor) 
x Proportion (%) of patients prescribed new oral anticoagulants (NOACs) previously treated 
with warfarin (A/B * 100 where A = all patients prescribed a NOAC previously treated 
with warfarin and B = all patients prescribed a NOAC) 
Proportion of patients prescribed the new medicine for concomitant treatment (good or bad), 
e.g.: 
x Proportion of patients initiated on telaprevir for the treatment of hepatitis C in 
combination with peginterferon alfa and ribavirin and who have had their genotype 
assessed 5,56 
Persistence of use, e.g.: 
x Proportion of patients persistent on NOACs after one year given concerns generally with 
persistence of medicines in patients with chronic asymptomatic conditions57 
 
d) Process indicators ± disease specific 
These indicators assess the rational use of a new medicine in relation to a disease/diagnosis or 
the proportion of patients with a certain condition initiated on a drug. These can be considered 
nationally, regionally or locally depending on the healthcare system and its funding9,42,58.  . 
Examples include the proportion of patients with hepatitis C who achieve a sustained 
virologic response (SVR) with new drugs such as the bocepravir and in combination. This 
may also be an intermediate outcome measure. However, there have been concerns with the 
objectivity of this measure 59,60 
 
Such indicators could also assess the proportion of patients initiated on a new medicine who 
are prescribed LWDFFRUGLQJWRDJUHHGUHFRPPHQGDWLRQVDQGQRWDV³RII-ODEHO´, e.g. Proportion 
of medicines prescribed that adhere to agreed guidelines in a predefined clinic, healthcare or 
national setting for use, e.g. for dabigatran9,42.   
 
e) Outcome indicators ± disease specific (with patient identity data) 
These indicators focus on the desired or not desired outcome of the new therapy, e.g., by 
using intermediate/surrogate markers: 
x Proportion of patients initiated on DPP-IV inhibitors achieving agreed HbA1c levels 
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x Proportion of patients with advanced cancers initiated on new cancer medicines achieving 
a desire response using a biomarker, e.g. bortezomib for the treatment of first relapse of 
multiple myeloma based on a 50% reduction in serum paraprotein levels (M-protein) by 
the fourth cycle 46,47 
x Proportion of patients with HIV achieving an agreed reduction in their viral load level 
 
They may also assess more relevant outcomes on morbidity and mortality post-launch: 
x % of patients achieving similar outcomes in practice versus Phase III results given 
potential differences in co-morbidities 9,40-42 
 
However, it is important to consider when developing indicators whether there are regional, 
gender, socioeconomic or other differentials in the distribution of the population 61 or 
geographical differences between countries or regions. 58,62-64 
 
Development of a testing protocol  
 
An indicator testing protocol has to apply to a multi-step and methodological process, as 
shown in Table 2. Such a protocol is a checklist of activities that need to be addressed in the 
development of quality indicators (for new innovative medicines but also in  general) that will 
be used in implementation plans around interventions to optimalize the introduction of new 
medicines. 
 
Table 2: Indicator testing protocol for the managed introduction of new medicines (Source: 
Based on Campbell et al 2011 32) 
 
Necessity 
x Analyzing the therapeutic arena ± current challenges, existing therapeutic recommendations, 
unmet need and the possibility for the new drug to address these needs 
x Assessment of current indicators and their applicability for the new drug 
x Each indicator should be underpinned by a published evidence base related to need (e.g. evidence 
of better efficacy, feasibility, safety or cost-effectiveness than existing drug)  
x Economic modelling 
Clarity  
x The indicator wording is clear and precise with unambiguous language that reflects a specific 
domain of quality   
x The indicator is within the control of the prescriber/provider that will be assessed 
Content validity 
x The indicator statement represents high quality care and is therefore a valid indicator of quality. 
There is sufficient evidence/ professional consensus to support it and there are clear benefits to the 
patient receiving the care (or the benefits significantly outweigh the risks).   
o Each indicator is underpinned by a published evidence base (e.g. a guideline or a well-
conducted clinical trial)  
o Adherence to the indicator is based on physicians/ staff adhering to the indicator providing a 
higher quality of care/service than those who are not doing so.  
o Likely patient benefit 
Technical feasibility and reliability of data extraction / data availability 
x Ability to write and integrate data extraction specifications into health information systems from 
all relevant providers  
x Ability to generate reproducible test reports within a reasonable time frame and budget from all 
relevant providers 
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Acceptability 
x Evaluation of the testing protocol 
x Alignment to patient values  
x Alignment to professional values  
Implementation 
x Discriminate validity: assessment of indicator to discriminate between providers 
x Sensitivity to change: assessment of current baseline of the indicator and potential change in 
baseline at the end of a piloting period 
x Clinical staff are able to interpret the indicator 
x Potential for gaming/manipulation is limited  
x Changes required to implement the indicator (i.e. acquisition and/or modification of IT; changes in 
physical capital/staffing; changes to regulation, policies and education). 
x Workload implications of implementing the indicator 
x Potential barriers among different stakeholders to the implementation of the indicators 
x Unintended consequences to the implementation of the indicator: positive or negative in nature 
(i.e. disruption to clinical or orgaQLVDWLRQDOZRUNIORZµVSLOORYHUV¶WKDWPD\EHQHJDWLYHGLYHUVLRQ
of effort) or positive (encouraging general quality improvement). 
 
Quality measures should be subjected to a testing protocol, with indicators assessed against 
key attributes 32,34. This protocol should address the development and implementation of the 
indicators and the interpretation of results/ outcomes. The most essential attribute is (a) 
validity: the degree to which the measured value reflects the characteristic it is intended to 
measure, both internal validity dealing with the accuracy of data and external validity dealing 
with issues such as interpretability, context and representativity, i.e. when achieving the 
indicator target is considered better quality and when the measure is a good translation of the 
clinical situation 15. Furthermore, indicators should be (b) relevant, (c) communicable, (d) 
objective (based on evidence) and (e) reliable. They should be independent of subjective 
judgement since it is known that self-reported data produces, for example, gross over-
estimations of adherence to guidelines 65  
 
However, the therapeutic context for the selected indicators needs to be described in order to 
understand the rationale behind the selected indicators. An example of such a summary is 
shown in Table 3 in relation to the quality of use of anticoagulants in Atrial Fibrillation.  
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Table 3. Therapeutic overview of Atrial Fibrillation: Rational behind the need for indicators 
on new oral anticoagulants (NOACs)  
 
Quality of anticoagulants in Atrial Fibrillation (necessity, clarity and content validity) 
Anticoagulation (AC) aims to reduce embolic stroke while achieving bleeding control 
Quality of AC/AF therapy requires initial assessment and regular clinical check-ups:  
- assessment and treatment of other risk factors for stroke, e.g., blood pressure and diabetes 
- scoring the patients stroke risk using CHADS2 or CHA2DS2 -VASc  
- WUHDWPHQWGHFLVLRQEDVHGRQSDWLHQW¶VULVN-score and individual patient factors that may affect the 
choice of medicine and dose regimen for optimal and stable exposure over time. These factors may 
include renal function and drug-GUXJLQWHUDFWLRQVDVZHOODVWKHSDWLHQWV¶DWWLWXGHVDQGFRPSOLDQFH 
- AC intensity control of warfarin PT-INR (range within 2-3), NOACs indirectly by, e.g., eGFR and 
clinical examination and patients reporting of nuisance bleeds or with direct laboratory measurements 
of the drug or its anticoagulation effect given appreciable variation in absorption42 
 
Potential unmet need & place in therapy of NOACs include: 
- underuse of warfarin and overuse of aspirin in AF due to feasibility problems and patient attitudes 
- frequent intensity checks and/or fluctuating AC intensity may be a problem in some patients 
- even though NOACs may add benefit for certain patients or in certain settings where AC control is 
suboptimal, it should be noted that patients on NOACs also have a narrow therapeutic window and 
that regular controls are needed 
- the limited availability of specific laboratory tests and antidotes to NOACs may cause problems in, 
e.g., emergency situations 
- comparable cost-effectiveness between warfarin and NOAC overall, but this may vary between 
different health systems and settings 
  
These relate to the attributes of necessity, clarity and content validity. The overall testing 
protocol (Table 2) should cover and test: (1) the necessity of new medicines, (2) data 
extraction from appropriate data sources to test technical feasibility and reliability, (3) cost-
effectiveness modeling to assess the budget impact and (4) implementation issues associated 
with introducing new medicines to test their acceptability, efficacy/effectiveness, workload, 
any associated education and training, patient views and unintended consequences 32. For 
example, the experience of introducing dabigatran showed increased prescriptions compared 
to warfarin in rural areas with less availability of warfarin monitoring clinics42. Examples of 
how the protocol can be applied to recently introduced anticoagulants (NOACs) are 
summarized in Table 4.  
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Table 4: Examples of application of new medicines to the indicator testing protocol Source: 
Based on Campbell et al 2011 32  
 
Testing protocol attribute Example 1 ± proportion of 
patients initiated on NOAC 
previously dispensed warfarin 
Example 2 ± proportion of 
patients treated with NOAC 
with annual renal function 
assessment (eGFR) 
Type of indicator (i.e. activity, 
process, outcome, systems) 
Process indicator, drug specific 
requiring patient identity drug 
dispensing data 
Process indicator, requiring 
access to laboratory 
data/medical records 
Necessity 
[pre-launch] 
Warfarin is a well documented 
drug with known safety profile 
and monitoring possibilities. 
Consequently it should be 
preferred for most patients 
Exposure levels of NOACs 
increased upon decreased renal 
function. This may increase 
bleeding risk that might be 
avoided by dose-reduction and 
switching. 
Clarity  
[pre-launch] 
Indicators based on 
prescriptions issued by the 
physician and/or dispensed at 
pharmacies 
Indicators based on patient 
follow up (measured by 
physicians) 
Content validity 
[pre-launch] 
Uncertain since the indicator 
encaptures no clinical data. 
Guidelines vary between 
countries9  
Stated in the Summary of 
Product Characteristics (SPC). 
Pharmacokinetic studies 
showing large variability in 
elimination due to renal 
function. 
Technical feasibility and 
reliability of data extraction / 
data availability 
[pre- and peri-and post launch] 
Requires patient-level pharmacy 
dispensing data readily 
available in many 
registries/reimbursement 
databases42 
May be extracted manually or 
automatic from medical records 
if properly recorded 
Acceptability 
[pre- and peri-and post launch] 
Dependent on how benefit and 
risk of NOAC vs warfarin is 
communicated to and perceived 
by patients and physicians 
Clearly relates to patient safety 
and should be obvious to both 
patients and physicians 
Implementation 
[pre- and peri- and post launch] 
Easy to use to compare 
practices and over time. Could 
be implemented with minimal 
workload for physicians and 
patients. 
 
A potential initial target may be 
>50%, but appropriate levels 
requires validation assessing 
clinical data. These target may 
change when new evidence is 
developed for NOACs 
Easy to use to compare 
practices and over time. Could 
in most instances be 
implemented with minimal 
workload for physicians and 
patients. 
 
Target level should be 100% 
and fixed over time. 
 
At a systems level post-launch, it is critical to collect follow-up data as well monitoring 
guideline/indicator adherence. In parallel, learn from the experience of the implementation of 
other new medicines i.e. dabigatran 9,41,42. 
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Attributes of the testing protocol for new medicines 
 
Necessity of a new medicine 
This constitutes a pre-launch activity that focuses as a prioritisation or filter stage to address 
the evidence base for the need of a new medicine either due to lack of efficacious drugs or 
safety, administration and persistence concerns. It addresses the incidence and prevalence of 
potential new users, the costs and effectiveness of existing medicines, the role of the new 
medicine in addressing multi-morbidity and economic modeling (including cost benefits; risk 
profile, etc.) 9,11,12,42. This assessment should summarise that there is sufficient evidence/ 
professional consensus to support the use of new medicines related to quantifiable benefits to 
the patient receiving the care (or the benefits significantly outweigh the risks) 32. 
 
Feasibility and reliability of data sources 
A common problem is that clinical data needed to develop indicators are not always easily or 
reliably available from routine data15,66. Administrative datasets seldom contain the clinical 
information required to assess the value of the new medicine. Data on drug prescribing is 
often only available in a structured form in administrative databases, designed for other 
purposes than the evaluation of quality or to provide feedback. For instance drug dispensing 
(or reimbursement/claims) data have no embedded information on diagnoses, no laboratory 
data or clinical measures. Consequently, these databases can rarely be used to derive valid 
patient- or disease-oriented indicators. An exception is when these databases apply unique 
identifiers of patients with the possibility of record-linkage to other clinical information. This 
is the case in the Nordic countries as well as in a number of reimbursement/claims databases 
in Europe, North America and Asia48,67. 
 
If data are to be aggregated, it requires careful planning and analysis, which illustrates the 
importance of having pre-determined aims and objectives that clearly set out the reasons why 
the data are being collected and what they will be used for. There is a need for available data 
sources, which can be used to extract data as appropriate for indicators, e.g. electronic 
medical records, drug dispensing databases, claims databases, disease registries and patient 
reported data. Several recent reports show how such data can be collected 68,69. Multiple data 
sources are required and there are limitations to aggregate data, i.e. patient level data is 
required in all datasets that are linked. Aggregated data are data without any possibility of 
identifying the number of patients prescribed/dispensed the drug; except where the aggregate 
is the patient count itself. Typical measures in these data sets are packages, prescriptions, 
DDDs or expenditure 49. Patient level data includes a unique patient identifier enabling 
estimation of the number of patients exposed to a drug (for combination of drugs) in any time 
period and with longitudinal data a history of prescribing/dispensing over time.   
  
Cost-effectiveness modeling  
Cost effectiveness models assess the value of interventions against two key factors: the 
benefits accrued and the costs incurred, to consider whether benefits accrued by a health 
authority or a patient outweigh the associated costs of development or provision of the 
service70. In terms of pharmaceuticals, the cost is the drug not a development or provision of 
service.  Budget impact analysis71 or modeling provides estimates of the likely impact of a 
new medicine on short- and longer-term annual budgets 72as well as help  assess the cost per 
Quality Adjusted Life Years (QALYs) gained73or to hypothesize a link from the new 
medicine with improved patient outcomes or health gains 32,74. This can often be linked to 
health gains associated with the treatment of a condition; for example, acute myocardial 
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infarction 32. The data from such models can be used to help derive possible indicators during 
the pre- to peri-launch phase. 
  
Implementation issues 
Implementation issues refer to identifying issues important to consider during the actual 
introduction of the new medicine. This includes understanding any baseline data in terms of 
existing prescribing rates, which also allows sensitivity to change analyses from any baseline, 
understanding any changes to practice or professional routine, behavior or workload 
associated with the introduction of the new medicine. It also involves unintended 
consequences of indicators.  
 
The key areas to address and consider before implementing indicators for new medicines are 
summarised in Box 1.  
 
Box 1: Key implementation factors for the introduction of new medicines * 
 
x Define quality and the attributes of quality to be measured 
x Address how to measure each aspect of defined quality 
x Decide who the customer is 
x Transparent recording of conflicts of interests of all stakeholders involved 
x Identify the appropriate unit of analyses (macro-meso-micro) and the availability of feasible and 
reliable data sources 
x 'DWDFROOHFWLRQV\VWHPVWKDWXQGHUSLQPHDVXUHPHQWEHIRUHTXDOLW\LPSURYHPHQWEHJLQV³NQRZ
\RXUEDVHOLQHV´ 
x Multiple approaches targeting quality and safety within a systems based strategy   
x A mix of structure, process and outcomes indicators 
x A mix of top-down and bottom-up approaches 
x Validated, field/pilot-tested indicators 
 
NB: *Based on Campbell et al 2010103 
 
These include acceptability, workload, informatics and infrastructure, intended and 
unintended consequences as well as the views of patients, the media, politicians and the 
general public. 
 
x Acceptability 
Any new indicator should be, as far as possible, acceptable to all stakeholders affected, either 
in its delivery (e.g. doctors) or receipt (e.g. patients) or oversight (e.g. health managers or 
funders) 11,28 . This includes alignment to professional values, policy-maker and 
commissioner/funder priorities and likely patient benefits. This requires in most cases 
pretesting of the acceptance of the indicators among the various stakeholder groups, including 
patients and the general public, or health professionals 75,76 . Indeed, professional 
organisations are often drivers of quality improvement initiatives. This makes it essential that 
medical professional organisations, as well as patients, be involved in the design, use and 
evaluation of new medicines using indicators. For example, in Sweden, the appropriate use 
and monitoring of uptake of TNF-alpha inhibitor drugs have been organized by the 
rheumatologists and not by any payer organizations or professional medical associations 77 . 
Similar initiatives are taken in other countries.78-80 
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x Workload 
It is important to understand any workload implications of introducing new medicines or 
vaccines and with implementing concomitant indicators. This includes any need to undertake 
staff training or patient education around the new medicine if it replaces an existing 
prescription or any additional workload associated with a new biomarker for a new medicine 
5,9. Additional workload will also result from the need for new data collection or data entry by 
patients and/or health professionals. This enables an estimation of the effort and costs 
associated with introducing new medicines that will also be part of any subsequent cost-
effectiveness analyses. 
 
x Informatics and infrastructure 
Any changes required in the way in which a health system or service provider is structured or 
staffed in order to be able to implement the indicator should be identified pre- and peri-launch 
(i.e. These might include changes to computer templates or IT systems, monitoring of risk 
sharing arrangements, changes in physical capital or staffing and changes to practice policies 
or culture such as the routinely entered data into registries or electronic health records) 9,42,68. 
In terms of the introduction of new medicines, any data collected must also be tested for the 
technical feasibility and reliability of the data extraction 32; i.e. the capacity to generate 
reproducible test reports within a reasonable time frame and within budget from all healthcare 
providers. 
 
x Intended and unintended consequences  
The intended consequences of the introduction of new medicines as measured by the 
indicators should be determined a priori and may include expectation of a beneficial effect on 
patient outcomes compared to existing treatments, the level of adherence to guidelines and the 
level of overall utilisation/cost of the new agent. This emphasizes the importance of involving 
and understanding the views of different stakeholders, which may be contradictory; for 
example, in relation to introducing new drugs especially new premium priced drugs where 
there are opportunity cost implications. Any non-appropriate influences by stake-holder 
groups have to be avoided by assuring that respected pharmacotherapeutic and clinical experts 
are the drivers for defining appropriate indicators. Any conflicts of interests are declared 
according to an established policy to ensure that recommendations are based on scientific 
evidence.20,58, 81  
 
Exploring potential unintended consequences should be integral to any indicator testing 
protocol prior to roll out: 7KHYDOXHRISLORWLQJLVDNLQWRDµUHDOLW\FKHFN¶ 32. These may 
include ensuring that maximising quality or cost-effectiveness of care for populations with a 
new drug is not at the expense of jeopardising the therapeutic needs of the individual patient 
82 given that there is significant variety in how individual patients respond to new treatments, 
including genetic factors 5,83 . Moreover, there is evidence that incentives based on specific 
aspects of care  lead to poorer recorded care for non-incentivised aspects of care 84.  
 
x PatientV¶ views and involvement   
Patient involvement in developing and using quality indicators is imperative. There is 
considerable variety in how paWLHQWVUHVSRQGWRWUHDWPHQWVGULYHQE\GLIIHUHQFHVLQSDWLHQW¶V
individual characteristics, pharmacodynamic/kinetic differences and genetics5,83,85. This 
requires a focus both on the 'technology' (i.e. tailored approach to avoid adverse drug 
reactions) and 'person' (i.e. genetic, medical or behavioural characteristics of patients 
including preferences). Data are required on patientV¶ experiences, attitudes and outcomes in 
terms of being potentially prescribed a new medicine and the subsequent impact on their 
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health status and quality of life. It is important to use new social-media and techniques to 
monitor patient attitudes and use of therapies; for example, using e-based techniques 86. 
 
Implicit in the definition of rational use of medicines and all of the quality indicators is the 
importance of incorporating the patient perspective and providing means for (direct) patient 
input on the indicators where appropriate.  Rational use requires patients to be knowledgeable 
about new medicines and have timely affordable access to appropriate medicines.  Two key 
structural barriers are a lack of coordinated care due to fragmented healthcare systems 5,87 and 
high drug costs or copayments 88,89.  Despite the plethora of drug information available 
through websites (both legitimate and otherwise), patients still depend on their physicians to 
prescribe medicines that take into consideration not only their clinical condition but also their 
emotional, social and economic situations to manage drug regimens that may be quite 
complex especially with multiple conditions and targeted therapies 90.   
 
Increasingly drug development, and particularly clinical trials, LQFOXGHWKHSDWLHQW¶VVXEMHFWLYH
assessment of his/her disease state and quality of life, which cannot be presumed from 
biometric or clinical tests alone 91.  This requires patient-reported outcome measures (PROs or 
PROMs).  Patients¶ perceptions of drug quality has significant impact on adherence, which is 
essential for achieving desired outcomes and avoiding adverse effects; although patient 
adherence to drug regimens is only about 50% 57,92.  The factors may be unintentional, such as 
complexity of the regimen or incompatibility with daily living (timing, frequency, preparation 
or storage).  They may also be intentional, namely the lack of perceived benefit (especially for 
preventive therapies) and/or serious adverse effects93.   
 
The consequences of non-adherence, and in some cases even partial non-adherence, to new 
medicines impact not only the patient outcomes but also the health system, resulting in 
increased hospitalizations and deteriorating health status.  The health economic impacts may 
be considerable, calling for the inclusion of patient adherence in calculating the 
pharmacoeconomics when comparing new and existing therapies 94. 
 
Discussion 
 
We have shown the opportunities and challenges in developing quality indicators for new 
medicines or vaccines and the importance of incorporating these in to a systems framework 
and testing protocol to monitor the quality of the use of new medicines.  To date, this has been 
a neglected area in indicator development. 
 
This has to be addressed with new medicines accounting for an increasing proportion of the 
overall costs for medicines and healthcare generally and is an area where pharmaceutical 
company  marketing activities are intense 10,46,86, 95-97.  It has been demonstrated in several 
studies that the quality of indicators for monitoring healthcare outcomes can lead to 
unintended consequences and lack many recommended parts. 32,98,99  Moreover, the observed 
influences of pharmaceutical companies on decisions about appropriate indicators suggests 
the need to consider the risk of conflicts of interests for the involved bodies and experts, 
which must be recorded clearly  when developing indicators  20,58, 81,97,100.  
 
We accept more research  is needed to measure how well such a framework for indicator 
development, and its embedded  indicators, would reflect health needs, capacity, structures 
and differences in outcome and to what extent certain differences in case-mix may influence 
the results. Tables 3 and 4 provide examples of how protocols for indicator development can 
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be applied to recently introduced NOACs for stroke prevention in atrial fibrillation to enhance 
appropriate prescribing. Follow-up studies have shown that excessive bleeding and deaths can 
be avoided by pre- and peri-launch activities including physician education and prescribing 
restrictions42.Such indicators should be seen as screening devices and should not be over-
LQWHUSUHWHG,QGLFDWRUVRQWKHLURZQFDQQRWSURYLGHµGHILQLWLYH¶HYLGHQFHRIVXFFHVVRUIDLOXUH
and should be used to raise questions, not provide answers 11,28,32.  
 
However, such a testing protocol and framework is intended to encourage transparency and 
dialogue between stakeholders including health authorities, physicians, patients and the 
pharmaceutical industry. This is because the pharmaceutical industry has been the principal 
source of information regarding new drugs enhanced by appreciable resources currently spent 
on marketing activities with physicians 38.   
 
We hope the suggested activities will stimulate a debate that will enhance innovation in 
pharmaceutical companies as well as the development of national drug strategies that find 
new ways of improved communication between payers and providers and between these 
groups and pharmaceutical companies, politicians and patient organisations. Without such 
dialogues, it may become increasingly difficult for European countries to continue to provide 
equitable and comprehensive healthcare within available budgets including funding for new 
innovative medicines. 
 
While indicators for new medicines, perhaps inevitably, focus on populations of patients this 
should not be at the expense of a focus on quality from the perspective of the needs of the 
individual patient 5,31,82. For example, knowledge about the influence of pharmacogenomics 
on response and toxicity of drug therapies increases the focus on personalised medicine in the 
development and introduction of new medicines and their assessment pre- and post launch 
with indicators.    
 
Summary 
 
Different countries need to learn from each other to achieve a transparent, consistent and 
equitable, and not just efficiency-based, process for managing the introduction of new 
medicines. Such a framework is intended to act as a testing protocol to maximize the 
appropriate rational introduction of a new medicine rather than acting as a barrier to the 
uptake of new medicines. It is essential to ensure appropriate funding for new valued drugs. 
The suggested framework and indicator testing protocol will be useful in assessing the 
utilization of new medicines and may be adapted to specific country health care settings 
worldwide.  There would be considerable benefits, and transparency of shared information, to 
all key stakeholders, including pharmaceutical companies, medical and professional 
organisations and patient organisations, by adherence to such a framework with the common 
aim of improved health outcomes for patients within finite resources.There is a need for 
greater collaboration between countries when looking to develop indicators, in particular 
when addressing orphan drugs or rare diseases5. International collaboration is especially 
important when evaluating new premium priced biological drugs to help ensure the optimal 
use of budgets for patients, physicians and health authorities given the appreciable number in 
development at envisaged high costs 5,25-27,101,102. 
 
In conclusion, we hope this paper will stimulate debate about the managed introduction of 
new medicines and strategies for effective introduction in different countries; as well as the 
need for an agreed indicator testing protocol that covers pre-launch and post-launch activities 
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and are transparent and consider risks of conflicts of interest. The introduction of new 
premium priced drugs is the greatest challenge to the European ideals of continued provision 
of equitable and comprehensive healthcare in Europe 10.  A more structured approach would 
help optimise the managed entry of new medicines and vaccines and enhance future funding.  
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